Leukemia

September 30, 2021

Trial Spotlight: Selina Luger on the PrE0905 Study for FLT3 Mutated Acute Myeloid Leukemia

This phase II trial is exploring the targeted cancer therapy gilteritinib, a tyrosine kinase inhibitor that kills leukemia cells by binding to the mutant FLT3 protein and blocking its activity